During limb development Pax3 positive myoblasts delaminate from the hypaxial dermomyotome of limb level somites and migrate into the limb bud where they form the dorsal and ventral muscle masses. Only then do they begin to differentiate and express markers of myogenic commitment and determination such as Myf5 and MyoD. However the signals regulating this process remain poorly characterised. We show that FGF18, which is expressed in the distal mesenchyme of the limb bud, induces premature expression of both Myf5 and MyoD and that blocking FGF signalling also inhibits endogenous MyoD expression. This expression is mediated by ERK MAP kinase but not PI3K signalling. We also show that retinoic acid (RA) can inhibit the myogenic activity of FGF18 and that blocking RA signalling allows premature induction of MyoD by FGF18 at HH19. We propose a model where interactions between FGF18 in the distal limb and retinoic acid in the proximal limb regulate the timing of myogenic gene expression during limb bud development.
Introduction
Amniote limb muscles are derived from myoblasts that originate in somites and migrate into developing limb buds (Chevallier et al., 1977; Christ and Brand-Saberi, 2002 ). Delamination and migration of these cells from the ventro-lateral lip of the hypaxial dermomyotome is regulated by Hepatocyte Growth Factor / Scatter Factor (HGF/SF) (Dietrich et al., 1999; Scaal et al., 1999) and requires the paired box transcription factor Pax3 (Franz et al., 1993) . Once in the limb myoblasts migrate to form the dorsal and ventral muscle masses. Only then do they begin to express the Myogenic Regulatory Factors (MRFs), basic helix loop helix transcription factors comprising Myf5, MyoD, myogenin and MRF4 which, ultimately, leads to differentiation of mature, functional myotubes (Buckingham et al., 2003; Mok and Sweetman, 2011) .
Myogenesis has been extensively studied during embryo development and provides an excellent paradigm to understand how inductive signals regulate differentiation.
Much of this work has focused on somites and extensive work has shown that interactions between Wnt, Shh and BMP signalling in both chicken and mouse embryos are critical for myogenesis (Borycki et al., 1999; Borycki et al., 1998; Hirsinger et al., 1997; Pourquie et al., 1996; Tajbakhsh et al., 1998) . However it is clear that the signalling events that control myogenesis in developing limbs are distinct from those in somites.
It has been suggested that limb myoblasts differentiate via a default pathway once they escape inhibitory BMP (Amthor et al., 1998) . Nevertheless other signals are involved in limb myogenesis (Christ and Brand-Saberi, 2002; Duprez, 2002; Venters et al., 2004) including Fibroblast Growth Factors (FGFs) (Edom-Vovard et al., 2001; Marics et al., 2002) and retinoic acid (RA) (Reijntjes et al., 2010) both of which have been reported to have inductive and repressive roles depending on concentration and cellular context. Recently Shh has also been shown to have an important role in the initiation of Myf5 and MyoD expression in limb myoblasts as well as their subsequent migration (Anderson et al., 2012; Hu et al., 2012) .
Several lines of evidence suggest that FGF receptors play important roles in limb myogenesis (Flanagan-Steet et al., 2000; Lagha et al., 2008; Marcelle et al., 1995; Marics et al., 2002) . Grafting of FGF soaked beads has been shown to negatively regulate muscle cell differentiation in somites (Sweetman et al., 2006) while retroviral FGF4 mediated expression can inhibit myogenesis in limbs (Edom-Vovard et al., 2001 ). However it has not been clearly established which of the FGF ligands are responsible for this activity in vivo and is further complicated by the ability of FGFs to induce their own negative regulators, resulting in complex feedback loops (Eblaghie et al., 2003; Smith et al., 2005) . Although ectopic FGF4 can inhibit limb bud muscle gene expression (Edom-Vovard et al., 2001) it is normally expressed in the apical ectodermal ridge (AER) which is probably too far from the developing myoblasts to play a role (Christen and Slack, 1999) while FGF10, which is expressed in the limb bud mesenchyme, is not able to induce myogenic gene expression in vivo (Ward et al., 2003) . Other FGFs expressed in the limb include FGF8 and FGF2 which, like FGF4, are expressed in the AER, and FGF12 and FGF13 which are intracellular FGFs and do not signal via tyrosine kinase receptors (Karabagli et al., 2002) . At least two FGF receptors, FGFR1 and FGFR4, are expressed in areas of the limb where myoblasts are located (Marcelle et al., 1995; Sheeba et al., 2010) and loss of function of either of these receptors disrupts limb muscle formation (Flanagan-Steet et al., 2000; Itoh et al., 1996; Marics et al., 2002) .
We wished to determine which FGF is likely to regulate limb bud myogenic gene expression in vivo. We identified FGF18 as a candidate because it is expressed in the limb bud mesenchyme (Maruoka et al., 1998; Ohuchi et al., 2000) and can signal through FGFR4 which is known to play a role in myogenesis (Kwiatkowski et al., 2008; Marics et al., 2002; Zhang et al., 2006) . FGF18 has been shown to regulate chondrocyte proliferation and hence bone growth in the developing limb (Liu et al., 2007) as well as hair follicle growth (Kawano et al., 2005; Leishman et al., 2013) and lung development (Elluru et al., 2009; Usui et al., 2004) but has not previously been implicated in myogenesis.
Interactions between retinoic acid and FGF signals have also been proposed to pattern the proximal-distal axis of the developing chick limb (Cooper et al., 2011; Mercader et al., 2000; Roselló-Díez et al., 2014; Roselló-Díez et al., 2011) . While this idea remains controversial (Cunningham et al., 2013) we hypothesised that interactions between these signals could provide a mechanism for controlling the timing of myoblast commitment and differentiation in the developing chicken limb. In this context it is worth noting that FGF and RA signalling pathways are known to interact during axis extension (del Corral et al., 2003) and that FGF18 expression is also regulated by RA signalling in both the trunk (Zhao and Duester, 2009 ) and the digits (Zhao et al., 2010) .
Our data suggest that FGF18 from the distal limb bud regulates the timing of expression of the myogenic markers Myf5 and MyoD through the ERK MAP kinase signalling pathway and that this is antagonised by high levels of retinoic acid in the proximal limb. We propose that interactions between these signalling pathways control the timing of progression of myoblasts from proliferative precursors to committed myocytes.
Materials and Methods
Probes and in situ hybridisation.
Dig-11-UTP (Roche) labelled antisense RNA probes were generated from full length cDNAs for Myf5 and MyoD cloned into pGEM (Promega) (Sweetman et al., 2008) were linearised with SacII and transcribed with SP6 RNA polymerase. Myogenin probes were generated from pBS-SK-Mgn linearised with SalI and transcribed with T7 RNA polymerase. Full length FGF18 was cloned from whole D5 embryo cDNA into pGEM using the following primers: FGF18F: ATGTATTCACTGCTCTCC, FGF18-HA-R (also includes sequence for c terminal HA tag):
TAAGCGTAATCTGGAACATCGTATGGGTAACTGGGGTTGGTGGGTCG. PCR was 5 performed with Phusion DNA polymerase (NEB), A-tailed and cloned into pGEM-T Easy. For Dig labeled probe transcription plasmid DNA was linearised with SacII and transcribed with SP6 RNA polymerase. MRF probes were as described in (Sweetman et al., 2008) and Pax3 probes as in (Abu-Elmagd et al., 2010) . In situ hybridisation was as described in (Smith et al., 2005) .
Immunostaining.
Embryos were harvested and dissected in cold PBS and fixed in 4% paraformaldehyde at 4°C overnight. Embryos were then washed in PBS for 30 mins at room temperature and then washed in 0.2% Triton X-100 at 4°C overnight. into slits cut into limb buds with a sharpened tungsten wire needle. Eggs were re-sealed with sellotape and incubated at 37.5°C for either 1, 6 or 24 hours.
Results

FGF18 expression in developing limb mesenchyme is consistent with a role in myogenic gene induction
As FGF18 expression has been described in developing chicken and mouse embryo limbs (Maruoka et al., 1998; Ohuchi et al., 2000) we first confirmed that it is expressed in chick embryos with a spatio-temporal pattern consistent with a role in myogenesis. We cloned a full length FGF18 cDNA for in situ hybridisation and examined its expression from HH stage 18 to HH stage 26, the period when myoblasts migrate into and differentiate in limb buds. At HH18 FGF18 is expressed in the tailbud, pharyngeal arches, nasal placode and isthmus, consistent with previous reports (Fig.1A ) (Ohuchi et al., 2000) . We first detected FGF18 in limb buds at HH20
where it is expressed in the distal mesenchyme of both fore-and hindlimbs ( 
Grafting FGF18 beads into developing limbs induces premature expression of
Myf5, MyoD and myogenin
To test directly if FGF18 can induce expression of muscle markers we grafted beads soaked in recombinant FGF18 protein into developing limbs at stages between HH19 and HH21 and analysed effects on myogenesis by in situ hybridisation with specific markers for different stages of muscle development. Ectopic expression of Myf5 in migratory myoblasts was detected after six hours incubation with FGF18 at HH19 (6/6 embryos, Fig.2A , B, M) and HH21 (7/7 embryos, Fig As Pax3 is expressed in proliferative myoblasts and downregulated as differentiation proceeds we also examined the effects of FGF18 on this gene. Although we did not observe large scale changes in expression in wholemount embryos with FGF18 beads grafted at HH21 (4/4 embryos) (Fig.2O ) sections through these limbs did show localised downregulation of Pax3 immediately adjacent to the FGF18 bead (Fig.2P) We also tested the ability of other FGFs to induce ectopic MyoD expression. FGF4 was able to induce MyoD expression (9/9 embryos, Fig.2Q ) while FGF10 was not 
FGF18 dependant MyoD expression requires ERK phosphorylation
To identify the signal transduction pathway responsible for ectopic MyoD expression following FGF18 bead application we used a phospho specific antibody staining to detect activiation of ERK MAP kinase. Within 1 hour of bead grafting we detected high levels of phospho-ERK in the mesenchyme surrounding the bead (3/3 embryos, To confirm that these results were specific to FGF receptor activation and not off target effects from FGF beads we co-grafted FGF18 beads with beads soaked in an inhibitor of all four FGFRs, FIIN 1 hydrochloride, which was able to block FGF18 induced MyoD expression (18/19 embryos, Fig.4A ). We also tested SU5402, another FGFR inhibitor which blocks signalling from FGFR1 and FGFR3, but this did not prevent FGF18 induced MyoD expression (8/10 embryos, Fig.4D ).
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As MEK is upstream of ERK and is responsible for its phosphorylation we tested if its activity was required for ectopic MyoD expression induced by FGF18 by grafting FGF18 and beads soaked in the MEK inhibitor U0126 adjacent to each other in developing limb buds for 6 hours. In these embryos U0126 beads blocked FGF18 induced expression of MyoD (12/13 embryos, Fig.4B ). To confirm the specificity of MEK in blocking FGF18 induced MyoD expression we also co-grafted FGF18 and beads soaked in the PI3K inhibitor LY294002. In these embryos FGF18 was still able to induce MyoD expression in the presence of LY294002 (8/11 embryos, Fig.4C ).
Control beads soaked in DMSO did not affect MyoD induction by FGF18 (6/6 embryos, Fig.4E ).
To test if inhibition of MEK could also block endogenous expression of MyoD we grafted U0126 beads into embryos at HH23, the point at which MyoD expression is first detected in limb buds by in situ hybridisation. U0126 grafted limbs had reduced MyoD expression when compared to contralateral unmanipulated limbs (8/10
embryos Fig.4F , G) while DMSO control beads did not (10/10 embryos Fig.4H, I ).
We then grafted beads soaked in either FIIN 1 hydrochloride, U0126 or DMSO into limb buds at HH21, harvested them after 24h and examined MyoD expression by comparing operated limb buds to contralateral controls. FIIN 1 hydrochloride beads abrogated MyoD expression, particularly in the dorsal muscle mass (9/11 embryos, Retinoic acid is known to have both positive and negative effects on limb muscle differentiation depending on concentration (Reijntjes et al., 2010) and it has also been suggested that interactions between retinoic acid and FGF signalling can influence proximal-distal limb patterning (Cooper et al., 2011; Mercader et al., 2000; Roselló-Díez et al., 2011) . Therefore we tested if RA signalling could affect the ability of FGF18 to induce myogenic gene expression. All trans retinoic acid (ATRA) soaked beads were grafted into forelimbs at HH21 and embryos harvested after 24h. MyoD expression was reduced in these forelimbs compared to contralateral limbs (9/9 embryos, Fig.5A, B) , consistent with previous reports (Reijntjes et al., 2010) . We then tested the ability of ATRA to block FGF18 induced MyoD expression directly by grafting FGF18 soaked beads adjacent to ATRA soaked beads into HH21 limb buds.
The majority of these embryos did not show ectopic MyoD expression (19/25 embryos, Fig.5C, D) . Control embryos grafted with FGF18 and beads soaked in DMSO at HH21 showed the expected induction of MyoD (6/6 embryos, Fig.4D ). We grafted beads soaked in BMS493, a retinoic acid antagonist, into HH19 embryos along with FGF18 soaked beads. In these embryos we saw ectopic expression of MyoD (8/9 embryos, Fig.5E , F) in contrast to embryos grafted with FGF18 alone at HH19 which do not express ectopic MyoD (Fig.2D) . Beads grafted into HH19 forelimbs soaked in BMS493 did not induce MyoD expression after 6h (10/10 embryos, Fig.5G ) and neither did control beads soaked in DMSO (6/6 embryos, Fig.5 H).
Discussion
Our results show that FGF18 in limb buds can induce expression of the key regulators of myogenesis, Myf5 and MyoD within 6 hours of bead grafting, and that this is mediated via ERK MAP kinase signalling. We also demonstrate differing temporal responses in that Myf5 is induced in both early (HH19) and later (HH21) limb buds while MyoD expression is only induced at later stages (HH21+). Finally we show that ectopically applied retinoic acid can inhibit the ability of FGF18 to induce MyoD while a retinoic acid antagonist, BMS493, can potentiate it in early limb buds.
We propose that interactions between these two signals regulate the timing of onset of Myf5 and MyoD expression in limb myoblasts (Fig.6A, B) .
FGF18 induces myogenic gene expression
Signals inducing myogenic expression have been extensively studied in somites and both Myf5 and MyoD are known to be induced by Wnt and Shh signalling in the epaxial myotome (Borycki et al., 1998; Tajbakhsh et al., 1998) and by Wnt and BMP in the hypaxial myotome (Dietrich et al., 1998; GeethaLoganathan et al., 2005; Marcelle et al., 1997) . In developing limbs the inductive signals are much less well characterised although several factors have been shown to inhibit early myogenesis including HGF/SF (Scaal et al., 1999) , retinoic acid (Reijntjes et al., 2010) , BMPs (Amthor et al., 1998) Shh A strong candidate for an inducer of myogenic genes in developing limbs is FGF signalling through FGFR4. FGFR4 is required during myogenic differentiation of C2C12 cells (Kwiatkowski et al., 2008) , is expressed in myoblasts as they migrate into the limb (Sheeba et al., 2010 ) and a dominant negative form of this receptor can inhibit Myf5, MyoD and MHC expression in limb myoblasts during development (Marics et al., 2002) . Our data are consistent with a role for FGFR4 as both FGF18 induced and endogenous MyoD expression was blocked by a pan-FGFR inhibitor (FIIN 1 hydrochloride) (Zhou et al., 2010) but not SU5402 which is known to block FGFR1 and 3 (Grand et al., 2004; Mohammadi et al., 1997) but has not been shown to directly affect FGFR4 activity.
However it has not been established which of the FGFs mediates this activity. Our data show that FGF4 or FGF8 soaked beads can induce MyoD in developing limbs in the same way as FGF18 (Fig.2 and data not shown) but these FGFs are normally restricted to the Apical Ectodermal Ridge, some distance from the differentiating myoblasts. Although FGFs can act over several cell diameters (Christen and Slack, 1999 ) the AER is probably too far from the myoblasts to be the source of an inductive signal for these cells and ERK phosphorylation in response to ridge FGFs does not seem to extend into the myogenic regions of the limb bud (Corson et al., 2003) . In contrast to our data, previous reports have shown that FGF4 in limb buds can lead to loss of myogenic gene expression (Edom-Vovard et al., 2001) ; we believe that this can be reconciled with our observations as the manipulations we performed were different in two important respects; our observations were carried out over very short time scales, making it likely that this conflicting data was uncovering a later function of FGF signalling, and we used bead grafts to deliver FGF while Edom-Vovard et al used RCAS retroviral misexpression. This makes it possible that we delivered higher doses of FGF which, in vitro, can lead to a switch between induction and repression of myogenesis (Pizette et al., 1996) . It is also possible that longer term exposure to FGF results in the upregulation of negative regulators of FGF signalling such as Sprouty or MAPK phosphatases (Eblaghie et al., 2003; Ozaki et al., 2001; Smith et al., 2005) which could also lead to the discrepancy between these results and those we observe.
Another potential candidate is FGF10 which is expressed in the limb bud mesenchyme (Ohuchi et al., 1997) but this has been shown not to induce myogenesis in vivo (Ward et al., 2003) and does not signal through FGFR4 (Zhang et al., 2006) . Based on the combination of its expression in the limb bud mesenchyme ( Fig.1 and (Ohuchi et al., 2000) , and its ability to signal through FGFR4 (Ellsworth et al., 2002; Xu et al., 2000) we identified FGF18 as a candidate inducer of limb bud myogenesis although our data does not rule out contributions from other FGFs in inducing limb mud myogenesis.
One observation from our data is that myogenic induction in these manipulations was mostly observed proximal to the bead. Although this might seem to conflict with our model, which would predict that myoblasts in the proximal limb bud should be more resistant to myogenic induction than more distal cells, this can be explained by the position of the myoblasts within the limb bud at these stages. Using Pax3 in situ hybridisation to label these migratory cells shows that the majority of myoblasts at HH 20/21 are found proximal to the position of grafted beads (Fig.6C) . Therefore it is no surprise that we detect the strongest response in this region of the limb. In addition myogenic cells introduced into the distal region of the limb bud show reduced myogenesis. Therefore it is also likely that signals in the distal limb are also operating to supress muscle gene expression (Robson and Hughes, 1996) . This could also explain why, in normal limb buds, myogenesis is seen first in the proximal then distal limb while our model, with proximal RA repressing and distal FGF18 inducing muscle gene expression, would predict the opposite. Combining our observations with the previous data showing that the distal limb can repress myogenesis resolves this conflict. There are many signalling molecules in the limb bud which have been shown to inhibit myogenic gene expression such as BMPs (Amthor et al., 1998) , Notch (Delfini et al., 2000) , HGF/SF (Scaal et al., 1999) and Shh and it is likely that interactions between RA, FGF18 and these repressive factors are also important for myoblast differentiation.
We also observe that in later manipulations loss of MyoD expression is seen in the dorsal but not the ventral muscle mass. Although it may be the case that the dorsal and ventral muscle masses are responding differently to the inhibitors we use, as they do to Shh signalling (Anderson et al., 2012; Hu et al., 2012) , it is also possible that this merely reflects the dorsal position of the bead following grafting.
FGF18 induced MyoD expression requires ERK signalling
Our data show that FGF18 beads induce phosphorylation of ERK MAP Kinase within one hour and that blocking this with the MEK inhibitor U0126 prevents ectopic MyoD expression. Similarly we show that U0126 can inhibit the onset of endogenous MyoD expression. However blocking ERK signalling over longer time scales does not inhibit MyoD and after a 24h incubation with U0126 beads manipulated limbs have similar MyoD expression to contralateral controls. It is possible that in these embryos the inhibitor is no longer active after this period of time or that induction of MyoD by FGF18 is regulating the timing of onset of MyoD expression rather than being absolutely required for myogenesis. Interestingly in FGF18 null mice skeletal development is also delayed but not abrogated (Liu et al., 2007) suggesting that the regulation of timing of differentiation may be a conserved feature of FGF18 function although muscle defects in this mouse have not been reported. In contrast long term effects on myogenesis are seen following grafts of the irreversible FGFR inhibitor FIIN 1 hydrochloride. This could reflect different stability of these inhibitors in vivo or it is possible that there are multiple phases of FGF signalling that are differently affected by these drugs. In this scenario U0126 can block the initial induction of MyoD through the ERK pathway but later induction is driven by FGF signalling through an alternative signalling pathway.
Interactions between FGF18 and retinoic acid control timing of MyoD
One striking feature of our data are the different temporal responses of Myf5 and MyoD to FGF18 beads. Myf5 is upregulated in early limb bud stages while MyoD is only induced prematurely after HH21; however this can be overcome by co-grafting FGF18 beads adjacent to beads soaked in BMS493, an antagonist of retinoic acid signalling. This implies that retinoic acid, which is synthesised in the embryonic flank, prevents premature differentiation of myoblasts as they migrate into the limb. As the limb bud expands they move away from the RA producing flank and towards the distal limb which expresses FGF18 as well as retinoic acid catabolising genes such as CYP26B1 (Reijntjes et al., 2003) . Therefore we propose a model where the timing of limb myoblast differentiation is controlled by these opposing activities with high levels of RA in the proximal limb bud maintaining a proliferative myoblast pool while FGF18 and lower levels of RA in the distal limb promote MyoD expression and differentiation (see Fig.6 ). The possibility that high concentrations of RA inhibit myogenesis while lower ones promote it (Reijntjes et al., 2010) could also help explain the proximal -distal direction of myogenesis, especially when combined with a distal inhibitory signal. Interestingly, a similar two signal model of opposing RA and FGF gradients has been proposed to pattern the proximal-distal limb axis in chicken embryos (Cooper et al., 2011; Mercader et al., 2000; Roselló-Díez et al., 2011) although work in mice has challenged this view (Cunningham et al., 2013) .
Differential responses of MRFs to FGF18
Although our data show that FGF18 can induce both Myf5 and MyoD it is not clear if these are independently regulated or if MyoD is downstream of Myf5 given that Myf5 can induce MyoD expression in chicken (Delfini and Duprez, 2004; Sweetman et al., 2008) and mouse (Relaix et al., 2013) embryos. It is possible that the developmental delay before migrating myoblasts are competent to respond to FGF18 and upregulate MyoD is due to a requirement for Myf5. If this is the case this could explain why Myf5 can be induced by FGF18 at HH19 but MyoD is not.
However while Myf5 is expressed before MyoD in chick limbs there is only partial overlap of these two genes (Delfini et al., 2000) . It is also clear from genetic ablation experiments in mice that there are Myf5 independent muscle cell lineages (Gensch et al., 2008; Haldar et al., 2008) but not MyoD independent ones (Wood et al., 2013) while cell labelling and culture experiments have also suggested that at least two distinct populations of cells contribute to limb myogenesis (Kablar et al., 2003; Picard and Marcelle, 2013) . It may be the case that the different temporal responses we observe in these assays are a result of distinct precursor populations of myoblasts in the developing limb. If so then we would expect to see Myf5 negative cells in the limb which respond to FGF18 by expression of MyoD.
An alternative explanation is that the transcriptional regulation of MyoD is more sensitive to RA mediated repression than Myf5. In this case ERK activation at HH19 can induce Myf5 but in these cells MyoD expression is not induced because the influence of RA at this time is still too strong, possibly because of interactions between RA and ERK response elements in the MyoD regulatory regions.
Distinguishing between these possibilities will provide important insights into the mechanisms of cell fate determination. 
